NCT04993079Completed
Clotild® Smart Guidewire System (CSGS) Evaluation in EndovascUlar Thrombectomy Procedure
Clotild® Smart Guidewire System Evaluation in Endovascular Thrombectomy Procedure
Source: ClinicalTrials.gov · Last updated 27 Feb 2026
Brief summary (registry, in English)
The purpose of this First-in-Human study is to evaluate the safety of using the Clotild® system to guide the endovascular thrombectomy (EVT) device to the clot location during EVT for the treatment of an acute ischemic stroke eligible to EVT, whatever the EVT device chosen. A secondary purpose is to assess the clinical performance, defined as the feasibility of measuring clot electrophysiological parameters in vivo during EVT procedures.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 45 (actual)
- First submitted
- 1 Sept 2020
- Start date
- Aug 2021
- Primary completion date
- Apr 2024
- Lead sponsor
- Sensome
- Diseases
- Stroke
- NCT number
- NCT04993079
What you commit to
- Study type: Interventional
- Participants enrolled: 45
- From Aug 2021 to the primary completion date, Apr 2024
- 3 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current participation in another investigational device or drug study that has not completed the primary endpoint or that clinically interferes with the current study endpoints
Other
- Patient having an intracranial occlusion other than M1 and/or MCA bifurcation, especially tandem occlusion and ICA (internal carotid artery) occlusion.
- Candidates not eligible for EVT based on neurointerventionist and/or neurologist investigators' opinion
- Pregnancy or lactating subjects
Who the study is looking for
- Clinical signs and symptoms consistent with the diagnosis of an acute ischemic stroke eligible for EVT
- M1 and/or MCA bifurcation arterial occlusion on Computed tomography angiography (CTA) or MRA (Magnetic resonance angiography) of an intracranial vessel amenable to EVT
- Informed Consent by subject, subject's Legally Authorized Representative (LAR) or anyone approved by the Ethics Committee (EC) and/or regulatory agencies to provide consent on behalf of the subject.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Liverpool Hospital Coordinator of this site? Confirm its status | Liverpool | Australia | Unknown status |
| Gold Coast University Hospital Coordinator of this site? Confirm its status | Southport | Australia | Unknown status |
| CHU Limoges Coordinator of this site? Confirm its status | Limoges | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.